Autres langues Aditxt, Inc.

Actions

ADTX

US0070256047

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
2,05 ^USD	-6,82%		-2,38%	-69,08%

16/04	Aditxt, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
02/01	Wall Street s'apprête à ouvrir 2024 en baisse en raison de la hausse des prix du pétrole et en prévision des données sur l'industrie manufacturière et la construction	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	06/05
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules	03/05
Aditxt, Inc. announced that it expects to receive $4.2 million in funding	03/05
Aditxt, Inc. announced that it expects to receive $150 million in funding	02/05
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03/04
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03/04
Appili Therapeutics To be Acquired by Aditxt, Inc.	02/04
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)	02/04
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	08/03
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	07/03
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023	01/02
Aditxt, Inc. Acquires Proprietary Electroencephalography Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications	31/01
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications	30/01
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	09/01
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	08/01
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million	08/01
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules	05/01
Aditxt, Inc. announced that it has received $6.000003 million in funding	04/01
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aditxt, Inc.

Actions

ADTX

US0070256047

Autres langues

Filtres